Quick Answer
Pasithea Therapeutics Corp. reported R&D Expense of $7.98 million for fiscal year 2025.
Pasithea Therapeutics Corp. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.98M | +10.9% |
| 2024 | $7.20M | -11.1% |
| 2023 | $8.10M | +203.9% |
| 2022 | $2.67M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.36M | -14.1% | -36.8% |
| June 30, 2025 | $2.15M | -8.9% | +24.2% |
| March 31, 2025 | $1.73M | -1.1% | +9.4% |
| September 30, 2024 | $1.58M | -2.7% | -32.9% |
| June 30, 2024 | $2.36M | +16.3% | +34.8% |
| March 31, 2024 | $1.75M | +59.6% | +7.7% |
| September 30, 2023 | $1.62M | +27.0% | -19.9% |
| June 30, 2023 | $2.03M | — | +85.0% |
- Pasithea Therapeutics Corp. showed an increase of +10.9% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Pasithea Therapeutics Corp.’s r&d expense has grown by 199.4% (from $2.67 million to $7.98 million).
- The most recent figure is from Pasithea Therapeutics Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: